Surgeon General’s Marijuana Warning Omits Crucial Context
Speaking about a recent federal advisory on marijuana, Dr.
Shefali Luthra
Trump’s Talk On Preexisting Conditions Doesn’t Match His Administration’s Actions
Delivering remarks on surprise medical billing, which is a concern that has drawn bipartisan interest, President Donald Trump waded into another high-profile health issue: making
Market Muscle: Study Uncovers Differences Between Medicare And Private Insurers
Private health insurance plans in 2017 paid more than twice what Medicare would have for those same health care services, says a sweeping new study from Rand Corp., a respected research organization.
Heart Drug Spotlights Troubling Trends In Drug Marketing
A company is marketing a drug intended as a preventive for people at risk for heart disease with stunning statistics but has not yet released details of its study.
At the end of September, Amarin Corp. teased some early findings for Vascepa, its preventive medicine for people at risk of heart disease. The claim was astounding: a 25 percent relative risk reduction for deaths related to heart attacks, strokes and other conditions.
Once Its Greatest Foes, Doctors Are Embracing Single-Payer
A shift is occurring, with many younger physicians concerned more about social justice than profit.
When the American Medical Association — one of the nation’s most powerful health care groups — met in Chicago this June, its medical student caucus seized an opportunity for change.
